Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ivermectin in scabies.

Pascal del Giudice1

  • 1Department of Infectious Diseases and Dermatology, Bonnet Hospital, Fréjus, France. del-giudice-p@chi-freujs-saint-raphael.fr

Current Opinion in Infectious Diseases
|April 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses.

American journal of clinical dermatology·2024
Same author

Erythema Migrans Caused by Borrelia spielmanii, France.

Emerging infectious diseases·2023
Same author

Id reaction following the treatment of a cutaneous larva migrans.

JAAD case reports·2023
Same author

<i>Rickettsia slovaca</i> "spotted fever".

JAAD case reports·2023
Same author

Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Decreased risk of rheumatic skin diseases in HIV/AIDS inpatients, potential role of antiretroviral therapy?

Clinical and experimental dermatology·2023
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Ivermectin, an anti-parasitic drug, shows promise as an oral treatment for human scabies. This offers a potential alternative to traditional topical scabicides.

Area of Science:

  • Medical Parasitology
  • Dermatology
  • Pharmacology

Background:

  • Standard scabies treatment relies on topical scabicides.
  • Ivermectin is a broad-spectrum anti-parasitic agent with veterinary and human (filariasis) applications.
  • Ivermectin is effective against nematodes and arthropods.

Purpose of the Study:

  • To evaluate ivermectin as an alternative oral therapy for human scabies.
  • To review worldwide reports on ivermectin's efficacy in scabies treatment.

Main Methods:

  • Review of global case reports and studies on ivermectin use in human scabies.
  • Analysis of ivermectin's pharmacological profile against scabies mites.

Main Results:

Related Experiment Videos

  • Worldwide reports suggest ivermectin is effective for human scabies.
  • Ivermectin presents a viable oral therapeutic option.

    • Conclusions:

    • Ivermectin is emerging as a significant alternative oral treatment for human scabies.
    • Further clinical trials may solidify ivermectin's role in scabies management.